S
Stockadora

Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4731 Reports
🤖 AI Analyzed
Recent
📄 Page 287 of 395
SUPERIOR GROUP OF COMPANIES, INC.
10-K March 3, 2026

Key Highlights

  • Achieved strong financial performance in 2025 with 5.8% revenue growth and a 25....
  • Leading provider of uniforms, branded products, and promotional merchandise acro...
  • Committed to shareholder returns, paying quarterly cash dividends totaling $0.60...
Read Analysis
🤖 AI Generated
ASCENT INDUSTRIES CO.
10-K March 3, 2026

Key Highlights

  • Strategic pivot to higher-margin Specialty Chemicals Segment by selling non-core...
  • Core Specialty Chemicals Segment revenue increased by 3% to $380 million with an...
  • Repurchased 1.5 million shares for $28 million, demonstrating management's confi...
Read Analysis
🤖 AI Generated
JAKKS PACIFIC INC
10-K March 2, 2026

Key Highlights

  • Strong international sales growth, reaching $154.1 million and 27.0% of total sa...
  • Maintained a healthy gross margin of approximately 34.5% in FY2025 through effec...
  • Generated an estimated $20 million in free cash flow in FY2025, demonstrating st...
Read Analysis
🤖 AI Generated
SEALED AIR CORP/DE
10-K March 2, 2026

Key Highlights

  • Strategic acquisitions, including Liquibox in Feb 2023, are expanding packaging ...
  • Active restructuring efforts through two major programs aim to streamline operat...
  • Proactive financial risk management includes hedging activities and debt optimiz...
Read Analysis
🤖 AI Generated
BJs RESTAURANTS INC
10-K March 2, 2026

Key Highlights

  • BJ's Restaurants Inc. delivered solid financial performance in fiscal year 2025,...
  • The company demonstrated strong operational growth by opening 4 new restaurants ...
  • BJRI significantly strengthened its financial health by reducing total debt to $...
Read Analysis
🤖 AI Generated
CERUS CORP
10-K March 2, 2026

Key Highlights

  • FDA approval of INTERCEPT red blood cell system unlocks a substantial new U.S. m...
  • Achieved 12% year-over-year revenue growth to $165 million, driven by global ado...
  • Projects 9% to 18% revenue growth for the upcoming fiscal year, signaling contin...
Read Analysis
🤖 AI Generated
SHORE BANCSHARES INC
10-K March 2, 2026

Key Highlights

  • SHORE BANCSHARES INC delivered a strong financial performance in 2023, with net ...
  • The company maintains excellent asset quality, with non-performing assets decrea...
  • It holds a robust financial position, exceeding all regulatory 'well-capitalized...
Read Analysis
🤖 AI Generated
BERKSHIRE HATHAWAY INC
10-K March 2, 2026

Key Highlights

  • Operating earnings rose by 17% to $37.4 billion, primarily driven by strong insu...
  • The company maintains an exceptionally strong financial position with substantia...
  • Disciplined share repurchase program continued, repurchasing approximately $9.2 ...
Read Analysis
🤖 AI Generated
BERKSHIRE HATHAWAY ENERGY CO
10-K March 2, 2026

Key Highlights

  • Strong financial performance with 8% revenue growth to $28.5 billion and 12% net...
  • Commitment to sustainable energy solutions, planning $7 billion in capital expen...
  • Diversified and resilient business model across regulated utilities (contributin...
Read Analysis
🤖 AI Generated
PLUG POWER INC
10-K March 2, 2026

Key Highlights

  • Reported total revenue of approximately $1.2 billion for fiscal year 2023, a 27%...
  • Actively building an integrated green hydrogen ecosystem, expanding operations a...
  • Strengthened key customer relationships with Amazon and Walmart, accounting for ...
Read Analysis
🤖 AI Generated
BGC Group, Inc.
10-K March 2, 2026

Key Highlights

  • Robust 2023 financial results with 8% revenue growth to $2.1 billion and 15% net...
  • Strategic acquisition of OTCGlobal for an estimated $250 million, enhancing tech...
  • Anticipates 5-7% revenue growth in fiscal year 2024, driven by acquisitions, org...
Read Analysis
🤖 AI Generated
GT Biopharma, Inc.
10-K March 2, 2026

Key Highlights

  • Progression of lead immunotherapy candidate GTB3650 into a Phase 1/2 study for r...
  • Promising safety profiles observed in initial dose-escalation phase of GTB3650 c...
  • Proprietary TriKE® platform positioned as a novel immunotherapy approach in onco...
Read Analysis
🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage